REGENXBIO Inc. (27)
Browse by Contract Category
Contracts
-
Compensation Program for Non-Employee Directors
(Filed With SEC on August 3, 2022)
-
Letter Agreement dated March 21, 2022 between the Company and The Trustees of the University of Pennsylvania
(Filed With SEC on May 4, 2022)
-
Settlement Agreement and Mutual Release dated November 12, 2021 between the Registrant and Abeona Therapeutics Inc
(Filed With SEC on March 1, 2022)
-
Royalty Purchase Agreement dated December 22, 2020 between the Registrant and entities managed by Healthcare Royalty Management, LLC
(Filed With SEC on March 1, 2021)
-
Fifth Amendment to License Agreement effective September 11, 2020 between the Company and The Trustees of the University of Pennsylvania
(Filed With SEC on November 4, 2020)
-
Third Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 24, LLC
(Filed With SEC on November 4, 2020)
-
Description of Securities
(Filed With SEC on March 1, 2022)
-
Collaboration and License Agreement dated September 10, 2021 between the Company and AbbVie Global Enterprises Ltd
(Filed With SEC on November 2, 2021)
-
Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan
(Filed With SEC on March 1, 2021)
-
Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan
(Filed With SEC on March 1, 2021)
-
Description of Securities
(Filed With SEC on March 1, 2021)
-
Underwriting Agreement, dated January 7, 2021, among REGENXBIO Inc. and BofA Securities, Inc., Morgan Stanley & Co. LLC and Barclays Capital Inc., as representatives of the...
(Filed With SEC on January 8, 2021)
-
Fifth Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 45, LLC
(Filed With SEC on November 4, 2020)
-
Compensation Program for Non-Employee Directors
(Filed With SEC on November 4, 2020)
-
First Amendment to License Agreement dated November 4, 2019 between the Registrant and Abeona Therapeutics Inc
(Filed With SEC on February 26, 2020)
-
Compensation Program for Non-Employee Directors
(Filed With SEC on February 26, 2020)
-
Description of Securities
(Filed With SEC on February 26, 2020)
-
Second Amendment to Lease dated November 4, 2019 between the Company and ARE-Maryland No. 24, LLC
(Filed With SEC on November 5, 2019)
-
Compensation Program for Non-Employee Directors
(Filed With SEC on August 7, 2019)
-
First Amendment to Lease dated May 28, 2019 between REGENXBIO Inc. and DS400OWNER, LLC
(Filed With SEC on June 3, 2019)
-
Lease dated May 16, 2016 between REGENXBIO Inc. and DS400OWNER, LLC, as successor-in-interest to 400 Madison Holdings, LLC
(Filed With SEC on June 3, 2019)
-
First Amendment to Lease dated April 23, 2019 between the Company and ARE-Maryland No. 24, LLC
(Filed With SEC on May 7, 2019)
-
Letter Agreement to Lease dated April 12, 2019 between the Company and ARE-Maryland No. 24, LLC
(Filed With SEC on May 7, 2019)
-
Fourth Amendment to License Agreement effective April 4, 2019 between the Company and The Trustees of the University of Pennsylvania
(Filed With SEC on May 7, 2019)
-
Employment Agreement effective April 17, 2019 between the Company and Steve Pakola, M.D
(Filed With SEC on May 7, 2019)
-
License Agreement dated November 4, 2018 between the Registrant and Abeona Therapeutics Inc
(Filed With SEC on February 27, 2019)
-
Compensation Program for Non-Employee Directors
(Filed With SEC on February 27, 2019)